Skip to main content
Livermore
Livermore
ZHEN

UBS Group AG

SEC CIK
0001610520
Latest filing
Aug 13, 2026

KLRS holding history

Kalaris Therapeutics, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

KLRS overviewAll 13F holders of KLRSFull Q2 2026 holdings

Shares (Q2 2026)
262,131
Value
$1.07M
% of portfolio
<0.1%
Quarters held
22
Since Q1 2021
Holdings of KLRS by UBS Group AG, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 2026262,131$1.07M<0.1%+255,947+4,138.9%AddedHolders
Q1 20266,184$35.7K<0.1%+3,493+129.8%AddedHolders
Q4 20252,691$22.7K<0.1%−2,561−48.8%ReducedHolders
Q3 20255,252$30.4K<0.1%+1,136+27.6%AddedHolders
Q2 20254,116$11.0K<0.1%−5,145−55.6%ReducedHolders
Q1 20259,261$74.4K<0.1%+3,804+69.7%AddedConverted for a 1-for-23 splitHolders
Q4 2024125,511$52.7K<0.1%+123,289+5,548.6%AddedHolders
Q3 20242,222$1.80K<0.1%−35,059−94.0%ReducedHolders
Q2 202437,281$27.0K<0.1%−18,215−32.8%ReducedHolders
Q1 202455,496$41.9K<0.1%−5,132−8.5%ReducedHolders
Q4 202360,628$41.2K<0.1%+24,372+67.2%AddedHolders
Q3 202336,256$78.0K<0.1%+28,145+347.0%AddedHolders
Q2 20238,111$27.6K<0.1%−8,025−49.7%ReducedHolders
Q1 202316,136$63.6K<0.1%−2,799−14.8%ReducedHolders
Q4 202218,935$97.1K<0.1%+18,117+2,214.8%AddedHolders
Q3 2022818$6.00K<0.1%−214−20.7%ReducedHolders
Q2 20221,032$4.00K<0.1%+3+0.3%AddedHolders
Q1 20221,029$7.00K<0.1%−62,876−98.4%ReducedHolders
Q4 202163,905$827.0K<0.1%+19,865+45.1%AddedHolders
Q3 202144,040$1.10M<0.1%+25,952+143.5%AddedHolders
Q2 202118,088$357.0K<0.1%−53,740−74.8%ReducedHolders
Q1 202171,828$1.68M<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.